These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 30948625)

  • 41. The impact of deep grey matter volume on cognition in multiple sclerosis.
    Lorefice L; Carta E; Frau J; Contu F; Casaglia E; Coghe G; Barracciu MA; Cocco E; Fenu G
    Mult Scler Relat Disord; 2020 Oct; 45():102351. PubMed ID: 32731200
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability.
    Roosendaal SD; Bendfeldt K; Vrenken H; Polman CH; Borgwardt S; Radue EW; Kappos L; Pelletier D; Hauser SL; Matthews PM; Barkhof F; Geurts JJ
    Mult Scler; 2011 Sep; 17(9):1098-106. PubMed ID: 21586487
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis.
    Adalsteinsson E; Langer-Gould A; Homer RJ; Rao A; Sullivan EV; Lima CA; Pfefferbaum A; Atlas SW
    AJNR Am J Neuroradiol; 2003; 24(10):1941-5. PubMed ID: 14625214
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Staging of cortical and deep grey matter functional connectivity changes in multiple sclerosis.
    Meijer KA; Eijlers AJC; Geurts JJG; Schoonheim MM
    J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):205-210. PubMed ID: 28986469
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiparameter MRI quantification of microstructural tissue alterations in multiple sclerosis.
    Lommers E; Simon J; Reuter G; Delrue G; Dive D; Degueldre C; Balteau E; Phillips C; Maquet P
    Neuroimage Clin; 2019; 23():101879. PubMed ID: 31176293
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis.
    Chard DT; Griffin CM; McLean MA; Kapeller P; Kapoor R; Thompson AJ; Miller DH
    Brain; 2002 Oct; 125(Pt 10):2342-52. PubMed ID: 12244090
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuroinflammatory component of gray matter pathology in multiple sclerosis.
    Herranz E; Giannì C; Louapre C; Treaba CA; Govindarajan ST; Ouellette R; Loggia ML; Sloane JA; Madigan N; Izquierdo-Garcia D; Ward N; Mangeat G; Granberg T; Klawiter EC; Catana C; Hooker JM; Taylor N; Ionete C; Kinkel RP; Mainero C
    Ann Neurol; 2016 Nov; 80(5):776-790. PubMed ID: 27686563
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E; Lee JC; Nakamura K; Rudick RA
    Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study.
    Agosta F; Absinta M; Sormani MP; Ghezzi A; Bertolotto A; Montanari E; Comi G; Filippi M
    Brain; 2007 Aug; 130(Pt 8):2211-9. PubMed ID: 17535835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant.
    Steenwijk MD; Geurts JJ; Daams M; Tijms BM; Wink AM; Balk LJ; Tewarie PK; Uitdehaag BM; Barkhof F; Vrenken H; Pouwels PJ
    Brain; 2016 Jan; 139(Pt 1):115-26. PubMed ID: 26637488
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of gray-matter multiple sclerosis lesions using double inversion recovery, diffusion, contrast-enhanced, and volumetric MRI.
    Parra Corral MA; Govindarajan ST; Stefancin P; Bangiyev L; Coyle PK; Duong TQ
    Mult Scler Relat Disord; 2019 Jun; 31():74-81. PubMed ID: 30951968
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brain grey matter perfusion in primary progressive multiple sclerosis: Mild decrease over years and regional associations with cognition and hand function.
    Testud B; Delacour C; El Ahmadi AA; Brun G; Girard N; Duhamel G; Heesen C; Häußler V; Thaler C; Has Silemek AC; Stellmann JP
    Eur J Neurol; 2022 Jun; 29(6):1741-1752. PubMed ID: 35167161
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long-standing multiple sclerosis.
    Steenwijk MD; Daams M; Pouwels PJ; J Balk L; Tewarie PK; Geurts JJ; Barkhof F; Vrenken H
    Hum Brain Mapp; 2015 May; 36(5):1796-807. PubMed ID: 25627545
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.
    Kim G; Chu R; Yousuf F; Tauhid S; Stazzone L; Houtchens MK; Stankiewicz JM; Severson C; Kimbrough D; Quintana FJ; Chitnis T; Weiner HL; Healy BC; Bakshi R
    Int J Neurosci; 2017 Nov; 127(11):971-980. PubMed ID: 28100092
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study.
    Obert D; Helms G; Sättler MB; Jung K; Kretzschmar B; Bähr M; Dechent P; Diem R; Hein K
    PLoS One; 2016; 11(9):e0162583. PubMed ID: 27636543
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.
    Pulizzi A; Rovaris M; Judica E; Sormani MP; Martinelli V; Comi G; Filippi M
    Arch Neurol; 2007 Aug; 64(8):1163-8. PubMed ID: 17698707
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
    Fisniku LK; Brex PA; Altmann DR; Miszkiel KA; Benton CE; Lanyon R; Thompson AJ; Miller DH
    Brain; 2008 Mar; 131(Pt 3):808-17. PubMed ID: 18234696
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
    Xiang B; Brier MR; Kanthamneni M; Wen J; Snyder AZ; Yablonskiy DA; Cross AH
    Mult Scler; 2022 Sep; 28(10):1515-1525. PubMed ID: 35196933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Unraveling the heterogeneous pathological substrates of relapse-onset multiple sclerosis: a multiparametric voxel-wise 3 T MRI study.
    Margoni M; Pagani E; Preziosa P; Gueye M; Azzimonti M; Rocca MA; Filippi M
    J Neurol; 2023 Aug; 270(8):3839-3850. PubMed ID: 37093395
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis.
    Tsagkas C; Huck-Horvath A; Cagol A; Haas T; Barakovic M; Amann M; Ruberte E; Melie-Garcia L; Weigel M; Pezold S; Schlaeger R; Kuhle J; Sprenger T; Kappos L; Bieri O; Cattin P; Granziera C; Parmar K
    Mult Scler; 2023 May; 29(6):702-718. PubMed ID: 36550626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.